Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Ajanta Pharma Ltd.

Ajanta Pharma

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹307.86 Cr.

EX-Date	Purpose
30 04 2021	Audited Results
29 07 2021	Quarterly Results
29 10 2021	Interim Dividend & Quarterly Results
28 12 2021	Buy Back of Shares
31 01 2022	Quarterly Results
10 05 2022	Bonus issue & Audited Results
28 07 2022	Quarterly Results
03 11 2022	Quarterly Results & Interim Dividend
01 02 2023	Quarterly Results
10 03 2023	Buy Back of Shares
05 05 2023	Audited Results
27 07 2023	Quarterly Results
27 07 2023	Interim Dividend & Quarterly Results
31 10 2023	Quarterly Results
31 01 2024	Second Interim Dividend & Quarterly Results
28 10 2024	Quarterly Results
30 01 2025	Quarterly Results
30 04 2025	A.G.M. & Audited Results
28 07 2025	Quarterly Results
03 11 2025	Quarterly Results & Interim Dividend

News

02-FEB-2023

Ajanta Pharma reports 30% fall in Q3 consolidated net profit

Total consolidated income of the company increased by 16.79% to Rs 1,006.70 crore for Q3FY23

11:29 AM

03-JUL-2023

Ajanta Pharma to enhance presence across select geographies in Asia, Africa

It intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics

12:09 PM

04-NOV-2022

Ajanta Pharma reports 20% fall in Q2 consolidated net profit

Total consolidated income of the company increased by 7.01% at Rs 978.45 crore for Q2FY23

11:50 AM

11-JUL-2023

Ajanta Pharma inks partnership with Credible Innovations

The company has chosen Credible as its strategic and implementation partner to enhance its ESG performance

03:12 PM

12-SEP-2022

Ajanta Pharma gets 2 procedural observation from USFDA for Dahej unit

USFDA has conducted inspection at Dahej unit from September 05, 2022 to September 09, 2022

12:28 PM

21-MAR-2025

Ajanta Pharma to expand manufacturing capacity

The investments required for the capacity addition is Rs 92 crore

02:09 PM

23-DEC-2022

Promoter entities sell 4.3% stake in Ajanta Pharma

The shares were offloaded at an average price of Rs 1,160.1 per scrip, taking the transaction value to Rs 637.22 crore

03:16 PM

26-JUN-2023

USFDA completes inspection at Ajanta Pharma’s Dahej formulation facility

At the end of inspection, USFDA issued no Form 483 to the said facility

10:05 AM

30-AUG-2023

Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules

The company has received 50 final ANDA approvals, out of which 41 are commercialized

06:15 PM